BHIVA views the involvement of patient and community representatives in the guideline
development process as both important and essential. The Writing Group included a patient representative who was involved in all aspects of the guideline development. The following measures have been/will be undertaken to disseminate and aid implementation of the guidelines: E-publication on the BHIVA website and the journal HIV Medicine Publication in HIV Medicine HSP tumor Shortened version detailing concise summary of recommendations E-learning module accredited for CME Educational slide set to support local and regional educational meetings National BHIVA audit programme There have been no major changes in recommendation. The prevalence data from the UK have been updated.
Safety: new data on efavirenz and raltegravir Prescribing: darunavir updated Resistance: data on mutations associated with the use of zidovudine monotherapy added; 21 days’ antiretroviral cover advocated to prevent mutations following single-dose nevirapine. IV zidovudine: guidance refined to include all viral loads > 1000 rather than 10 000 HIV RNA copies/mL plasma. Hepatitis: information added on telaprevir and boceprevir. Mode of delivery: new data on transmission rates by mode of delivery at low viral load (50–399 copies/mL) added, strengthening the evidence for the existing recommendation to consider Dabrafenib chemical structure PLCS at these viral loads. Infant diagnostic section has been updated. No other change to paediatric section including infant feeding advice. The guidelines will Ceramide glucosyltransferase be next fully updated and revised in 2017. The Writing Group will, however, continue to confer regularly to consider new information from high-quality studies and publish amendments and addendums to the current recommendations prior to the full revision date where this is thought to be clinically important to ensure continued best clinical practice. 4.1.1 Sexual health screening is recommended for pregnant
women newly diagnosed with HIV. Grading: 1B 4.1.2 For HIV-positive women already engaged in HIV care who become pregnant sexual health screening is suggested. Grading: 2C 4.1.3 Genital tract infections should be treated according to BASHH guidelines. Grading: 1B 4.2.1 Newly diagnosed HIV-positive pregnant women do not require any additional baseline investigations compared with non-pregnant HIV-positive women other than those routinely performed in the general antenatal clinic. Grading: 1D 4.2.2 HIV resistance testing should be performed prior to initiation of treatment (as per the BHIVA guidelines for the treatment of HIV-1 positive adults with antiretroviral therapy 2012), except for late-presenting women. Post short-course treatment a further resistance test is recommended to ensure that mutations are not missed with reversion during the off-treatment period. Grading: 1D 4.2.